Back to Menu
Chordoma is a low-grade malignant tumor derived from embryonic notochordal remnants and accounts for approximately 1%–4% of primary bone tumors. It most commonly occurs in the sacrococcygeal region (50%), skull base (35%), and other segments of the spine (15%). It is characterized by strong local invasiveness and a high recurrence rate.
1. Conventional chordoma
The most common subtype (85%–90%), composed of physaliphorous cells. It typically grows relatively slowly but is locally aggressive.
2. Dedifferentiated chordoma
A high-grade subtype with sarcomatous components, showing aggressive behavior and a higher likelihood of metastasis, with an unfavorable prognosis.
3. Chondroid chordoma
Shows cartilaginous differentiation histologically, most often located at the skull base, accounting for approximately 5%–8%, with a relatively better prognosis.
4. Poorly differentiated chordoma
More common in children and characterized by loss of INI1 expression; it is highly aggressive and has a poor prognosis, requiring distinct management.
1. Notochordal remnants
Incomplete regression of notochordal tissue during embryogenesis provides the basis for chordoma development.
2. Genetic alterations
Overexpression of the brachyury gene is a key driver of tumorigenesis and an important genetic feature in sporadic chordoma.
3. Genetic predisposition
Patients with hereditary disorders such as tuberous sclerosis complex may have increased susceptibility due to underlying genetic defects.
4. Radiation exposure
A history of prior head and neck radiotherapy is a recognized risk factor and may induce malignant transformation of notochordal remnants.
5. Trauma-related factors
Repeated local trauma may promote cellular proliferation and contribute to tumor development on the background of residual notochordal tissue.
1. Regular health examinations
High-risk populations should undergo periodic imaging surveillance for early detection and timely intervention.
2. Genetic counseling
Individuals with a family history should receive genetic counseling to assess risk and develop monitoring plans.
3. Lifestyle optimization
Maintain balanced nutrition and moderate exercise to support immunity and avoid local trauma.
4. Pain monitoring
Persistent pain should be taken seriously, with prompt medical evaluation to avoid diagnostic delay.
5. Functional rehabilitation
Structured postoperative rehabilitation helps maintain joint mobility and prevents muscle atrophy.
6. Psychological support
Professional psychological counseling can address anxiety and depression and improve treatment adherence.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that chordoma grows slowly but is locally destructive, with a high recurrence rate and potential to cause paralysis. Surgery-based multimodal management is pivotal and should be individualized according to tumor location. Early consultation and MDT-based multidisciplinary collaboration are recommended to preserve organ function and prolong survival.
Chordoma is a low-grade malignant tumor derived from embryonic notochordal remnants and accounts for approximately 1%–4% of primary bone tumors. It most commonly occurs in the sacrococcygeal region (50%), skull base (35%), and other segments of the spine (15%). It is characterized by strong local invasiveness and a high recurrence rate.
1. Conventional chordoma
The most common subtype (85%–90%), composed of physaliphorous cells. It typically grows relatively slowly but is locally aggressive.
2. Dedifferentiated chordoma
A high-grade subtype with sarcomatous components, showing aggressive behavior and a higher likelihood of metastasis, with an unfavorable prognosis.
3. Chondroid chordoma
Shows cartilaginous differentiation histologically, most often located at the skull base, accounting for approximately 5%–8%, with a relatively better prognosis.
4. Poorly differentiated chordoma
More common in children and characterized by loss of INI1 expression; it is highly aggressive and has a poor prognosis, requiring distinct management.
1. Notochordal remnants
Incomplete regression of notochordal tissue during embryogenesis provides the basis for chordoma development.
2. Genetic alterations
Overexpression of the brachyury gene is a key driver of tumorigenesis and an important genetic feature in sporadic chordoma.
3. Genetic predisposition
Patients with hereditary disorders such as tuberous sclerosis complex may have increased susceptibility due to underlying genetic defects.
4. Radiation exposure
A history of prior head and neck radiotherapy is a recognized risk factor and may induce malignant transformation of notochordal remnants.
5. Trauma-related factors
Repeated local trauma may promote cellular proliferation and contribute to tumor development on the background of residual notochordal tissue.
1. Regular health examinations
High-risk populations should undergo periodic imaging surveillance for early detection and timely intervention.
2. Genetic counseling
Individuals with a family history should receive genetic counseling to assess risk and develop monitoring plans.
3. Lifestyle optimization
Maintain balanced nutrition and moderate exercise to support immunity and avoid local trauma.
4. Pain monitoring
Persistent pain should be taken seriously, with prompt medical evaluation to avoid diagnostic delay.
5. Functional rehabilitation
Structured postoperative rehabilitation helps maintain joint mobility and prevents muscle atrophy.
6. Psychological support
Professional psychological counseling can address anxiety and depression and improve treatment adherence.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that chordoma grows slowly but is locally destructive, with a high recurrence rate and potential to cause paralysis. Surgery-based multimodal management is pivotal and should be individualized according to tumor location. Early consultation and MDT-based multidisciplinary collaboration are recommended to preserve organ function and prolong survival.